Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Breast J ; 25(5): 942-947, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31165586

RESUMEN

The utilization rate of RT increased from 64.4% in 2011 to 70.3% in 2015. After BCS and mastectomy, 97.3% and 26.1% of the patients received RT, respectively. For patients undergoing BCS and mastectomy, lower age and ER + tumours were associated with higher RT utilisation rates. After mastectomy, also larger tumour sizes, lymph node involvement, grade-2 and 3 tumours and diagnosis in more recent years were associated with higher RT use.


Asunto(s)
Neoplasias de la Mama/radioterapia , Radioterapia/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Femenino , Humanos , Mastectomía Segmentaria/estadística & datos numéricos , Persona de Mediana Edad , Países Bajos
2.
Front Pediatr ; 9: 707650, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34722416

RESUMEN

Background: It has been suggested that children and infants can develop multisystem inflammatory syndrome in children (MIS-C) in response to a SARS-CoV-2 infection and that Black children are overrepresented among cases. The aim of the current study was to quantify the association between Black, Asian, or other non-White genetic background and COVID-19-related MIS-C in children and infants. Methods: Eight different research groups contributed cases of MIS-C, potentially related to SARS-CoV-2 infection. Several sensitivity analyses were performed, including additional data available from the literature. Analyses were stratified by geographical region. Results: Seventy-three cases from nine distinct geographical regions were included in the primary analyses. In comparison to White children, the relative risk for developing MIS-C after SARS-CoV-2 infection was 15 [95% confidence interval (CI): 7.1 to 32] for Black children, 11 (CI: 2.2 to 57) for Asian, and 1.6 (CI: 0.58 to 4.2) for other ethnic background. Conclusion: Pediatricians should be aware of the fact that the risk of COVID-19-related MIS-C is severely increased in Black children.

3.
Clin Infect Dis ; 48(5): e53-6, 2009 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-19191633

RESUMEN

Microbial cure of chlamydia proctitis (lymphogranuloma venereum [LGV] and non-LGV) with doxycycline treatment was evaluated by chlamydia DNA and RNA persistence in anal swab specimens. In LGV proctitis, RNA persisted for up to 16 days. In non-LGV chlamydia proctitis, DNA was undetectable after 7 days. These findings support the Centers for Disease Control and Prevention's treatment recommendation of a 21-day doxycycline regimen for LGV proctitis and a 7-day regimen for non-LGV chlamydia proctitis. Delayed microbial cure of LGV proctitis should be considered in improved treatment regimens.


Asunto(s)
Antibacterianos/uso terapéutico , Chlamydia trachomatis/efectos de los fármacos , Doxiciclina/uso terapéutico , Linfogranuloma Venéreo/tratamiento farmacológico , Proctitis/tratamiento farmacológico , Canal Anal/microbiología , Chlamydia trachomatis/aislamiento & purificación , ADN Bacteriano/aislamiento & purificación , Humanos , Masculino , ARN Bacteriano/aislamiento & purificación , Factores de Tiempo
4.
J Geriatr Oncol ; 10(2): 330-336, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30131236

RESUMEN

BACKGROUND: The aim of this study was to analyze the distant metastases-free survival (DMFS), and disease-specific survival (DSS) after breast-conserving therapy (BCT) in older patients with breast cancer in a large, population-based, single-center cohort study with long-term follow-up. MATERIAL AND METHODS: Analyses were based on 1,425 women aged 65 years and older with breast cancer treated with BCT. Patients were divided in three age categories: 65 - 70 years, 71 - 75 years, and >75 years. The study period extended over 30 years, divided in three decades. Multivariate survival analysis was carried out using Cox regression analysis. RESULTS: The two youngest age categories showed significant improvements over time in 12-year DMFS and DSS. For women aged 65 - 70 years, this improvement was noted in stage I and stage II disease, while for women aged 71 - 75 years this was mainly in stage II tumors. Women >75 years of age did not show any improvement over time, regardless of stage. CONCLUSION: Among older Dutch women with breast cancer, outcomes with regard to DMFS and DSS after BCT differ between various age categories, showing the least gain in the very old.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/terapia , Carcinoma Ductal de Mama/terapia , Carcinoma Lobular/terapia , Mastectomía Segmentaria , Radioterapia Adyuvante/métodos , Anciano , Anciano de 80 o más Años , Axila , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/patología , Carcinoma Lobular/mortalidad , Carcinoma Lobular/patología , Quimioterapia Adyuvante , Femenino , Humanos , Estudios Longitudinales , Escisión del Ganglio Linfático , Márgenes de Escisión , Análisis Multivariante , Metástasis de la Neoplasia , Estadificación de Neoplasias , Países Bajos , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Hipofraccionamiento de la Dosis de Radiación , Biopsia del Ganglio Linfático Centinela , Análisis de Supervivencia
5.
Clin Epidemiol ; 10: 1391-1399, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30323682

RESUMEN

Evidence-based medicine has become associated with a preference for randomized trials. Randomization is a powerful tool against both known and unknown confounding. However, due to cost-induced constraints in size, randomized trials are seldom able to provide the subgroup analyses needed to gain much insight into effect modification. To apply results to an individual patient, effect modification needs to be considered. Results from randomized trials are therefore often difficult to apply in daily clinical practice. Confounding by indication, which randomization aims to prevent, is caused by more severely ill patients being less or more likely to be treated. Therefore, the prognostic indicators that physicians use to make treatment decisions become confounders. However, these same prognostic indicators are also effect modifiers. This is in fact exactly why they are relevant to decision-making. We use simple, fictive numerical examples to illustrate these concepts. Then we argue that if we would record all relevant variables, it would simultaneously solve the problem of confounding by indication and allow quantification of effect modification. It has previously been argued that it is practically more feasible to "simply" randomize treatment allocation, than to adequately correct for confounding by indication. We will argue that, in the current age of evidence-based medicine and highly regulated randomized trials, this balance has shifted. We therefore call for better observational clinical research. However, careless acceptance of results from poorly performed observational research can lead clinicians seriously astray. Therefore, a more interactive approach toward the medical literature might be needed, where more room is made for scientific discussion and interpretation of results, instead of one-way reporting.

6.
Int J Radiat Oncol Biol Phys ; 98(4): 843-849, 2017 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-28366575

RESUMEN

PURPOSE: To investigate whether the Geriatric 8 (G8) and the Timed Get Up and Go Test (TGUGT) and clinical and demographic patient characteristics were associated with acute toxicity of radiation therapy and noncompliance in elderly cancer patients being irradiated with curative intent. METHODS AND MATERIALS: Patients were eligible if aged ≥65 years and diagnosed with breast, non-small cell lung, prostate, head and neck, rectal, or esophageal cancer, and were referred for curative radiation therapy. We recorded acute toxicity and noncompliance and identified potential predictors, including the G8 and TGUGT. RESULTS: We investigated 402 patients with a median age of 72 years (range, 65-96 years). According to the G8, 44.4% of the patients were frail. Toxicity grade ≥3 was observed in 22% of patients who were frail according to the G8 and 9.1% of patients who were not frail. The difference was 13% (confidence interval 5.2%-20%; P=.0006). According to the TGUGT 18.8% of the patients were frail; 21% of the frail according to the TGUGT developed toxicity grade ≥3, compared with 13% who were not frail. The difference was 7.3% (confidence interval -2.7% to 17%; P=.11). Overall compliance was 95%. Toxicity was most strongly associated with type of primary tumor, chemotherapy, age, and World Health Organization performance status. Compliance was associated with type of primary tumor and age. CONCLUSIONS: The usefulness of the TGUGT and G8 score in daily practice seems to be limited. Type of primary tumor, chemoradiotherapy, age, and World Health Organization performance status were more strongly associated with acute toxicity. Only chemoradiotherapy and age were associated with noncompliance. Overall the compliance was very high. To allow better-informed treatment decisions, a more accurate prediction of toxicity is desirable.


Asunto(s)
Quimioradioterapia/efectos adversos , Quimioradioterapia/estadística & datos numéricos , Anciano Frágil/estadística & datos numéricos , Evaluación Geriátrica/métodos , Neoplasias/terapia , Cooperación del Paciente/estadística & datos numéricos , Factores de Edad , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Antineoplásicos/efectos adversos , Neoplasias de la Mama/terapia , Carcinoma de Pulmón de Células no Pequeñas/terapia , Intervalos de Confianza , Neoplasias Esofágicas/terapia , Femenino , Neoplasias de Cabeza y Cuello/terapia , Humanos , Neoplasias Pulmonares/terapia , Masculino , Gravedad del Paciente , Neoplasias de la Próstata/terapia , Neoplasias del Recto/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA